

29 November 2024

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Results of 2024 Annual General Meeting

Aptamer Group plc (AIM: APTA), the developer of novel Optimer[®] binders to enable innovation in the life sciences industry, today announces that the results of voting on the resolutions put to shareholders at its Annual General Meeting (AGM) held earlier today at 10:00 am at the offices of Aptamer Group, Windmill House, Innovation Way, York, YO23 1LR, all Resolutions were duly passed.

Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 5 November 2024 and the full poll results will be made available on the Aptamer website later today.

- Ends -

For further information, please contact:

Aptamer Group plc	+44 (0) 1904 217 404
Arron Tolley, Chief Executive Officer	
SPARK Advisory Partners Limited - Nominated Adviser	+44 (0) 20 3368 3550
Andrew Emmott / Adam Dawes	
Turner Pope Investments (TPI) Limited - Broker	+44 (0) 20 3657 0050
James Pope / Andrew Thacker	
Northstar Communications Limited - Investor Relations	+44 (0) 113 730 3896
Sarah Hollins	

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer[®] platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers. Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over 170 billion.

Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.

To register for news alerts by email go to <https://aptamergroup.com/investors/investor-news-email-alerts/>.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGFKLFLZFLBFBX